Evaluation of Analgesia for Spine Fusion Elective Surgery in Children
Launched by SENTHIL SADHASIVAM · Oct 1, 2024
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well a new method using methadone can help children recover after spinal surgery for a condition called idiopathic scoliosis, which is a sideways curvature of the spine. The study will compare this new recovery plan to the current standard care that children usually receive after surgery. To decide who gets which treatment, children will be randomly assigned to one of the two groups, similar to flipping a coin.
The trial is open to children aged 10 to 17 who are scheduled for spinal surgery. However, there are certain conditions that might prevent some children from participating, such as having severe health issues or allergies to certain medications. While the study is not yet recruiting participants, families can expect their child to receive either the new methadone-based recovery approach or the usual care after surgery, contributing to important research that could improve recovery outcomes for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants aged 10-\<18yrs for PSF trial
- • ASA physical status 1\&2
- • Undergoing PSF for idiopathic scoliosis
- • Participant or legal guardian can speak and read English or Spanish
- Exclusion Criteria:
- • Pregnant patients
- • American Society of Anesthesiologists (ASA) Physical Status 3 or above
- • Methadone/oxycodone allergy
- • Preoperative prolonged QTc more than 460 msec (-30 days to 0 day)
- • Subjects undergoing concomitant treatment with known cytochrome P450 inhibitors included in methadone labeling (i.e. macrolides (e.g. erythromycin), azole-antifungal agents (e.g. ketoconazole, voriconazole), protease inhibitors (e.g. ritonavir), fluconazole, SSRIs (e.g. sertraline, fluvoxamine)
- • Preoperative opioid use within 30 days before surgery
- • History of severe sleep apnea (have a sleep study with an AHI index score more than 10 or clinical signs of sleep disordered breathing - snoring, daytime drowsiness)
- • Significant liver, kidney, neurological disease, developmental delay, or any other co-existing medical condition per discretion of the clinical investigator
About Senthil Sadhasivam
Senthil Sadhasivam is a dedicated clinical trial sponsor with a focus on advancing medical research through innovative and rigorous study designs. Committed to improving patient outcomes, Sadhasivam leverages extensive expertise in clinical methodologies and regulatory compliance to facilitate the development of new therapies. By fostering collaborations with healthcare professionals and research institutions, he aims to contribute to the understanding of complex medical conditions and enhance treatment options available to patients. With a strong emphasis on ethical practices and patient safety, Senthil Sadhasivam is positioned as a reliable partner in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Senthilkumar Sadhasivam, MD
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported